Close up of older male teenager with visible acne. Close up of older male teenager with visible acne.

TWYNEO CREAM

Fight acne fast

with the 2-in-1 that’s never been done

Microencapsulation technology

The rapid efficacy you demand and tolerability they deserve.1-4

Not an actual patient.
FOR PATIENTS AGES 9 AND UP1

Acne's first-ever
.1% tretinoin & 3% BPO 2-in-11,2

The once-daily cream that finally unites 2 proven ingredients for a never-before-seen fixed-dose combination. Using microencapsulation technology, TWYNEO cream helps patients stay on track with rapid results and tolerability with transient effects over time.1-4

Photo of TWYNEO cream box with bottle next to it.
MICROENCAPSULATION

Combination meets innovation2

EXPLORE FURTHER
Microencapsulation logo
Younger male teenager with visible acne smiling confidently at camera.
Not an actual patient.
RESULTS

Potent doses for rapid results3*

SEE DATA
SAFETY

Favorable tolerability1,3,4

LEARN MORE
Female teenager holding a bottle of TWYNEO cream playfully in front of her face.
Not an actual patient.
Older male teenager smiling confidently at camera.
Not an actual patient.
SATISFACTION

High rates of patient-reported satisfaction3,4

VIEW RESULTS
Image of the Galderma CareConnect Savings card. Image of the Galderma CareConnect Savings card.

Don't let your patients break the bank fighting breakouts

DISCOVER SAVINGS

BPO=benzoyl peroxide.

*

Noninflammatory lesion reduction at Week 2.3,4

References: 1. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2021. 2. Sol-Gel Technologies Ltd. Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-Gel Advanced Topical Therapy. July 27, 2021. Accessed August 20, 2021. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-04; May 28, 2020. 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-05; June 5, 2020.